Making the Switch in Atopic Dermatitis: Optimizing Treatment Targets With JAK Inhibitors - Episode 2
AHEAD Recommendations: Overcoming Therapeutic Inertia to Achieve Treatment Targets
Panelists discuss how the AHEAD recommendations establish evidence-based treatment targets requiring simultaneous achievement of skin clearance (Eczema Area and Severity Index [EASI]-90) and itch relief (itch score 0-1) within 3 to 6 months, fundamentally changing the standard of care by incorporating patient-reported outcomes alongside physician assessments.
Video content above is prompted by the following:
The AHEAD (Aiming High in Eczema/Atopic Dermatitis) recommendations have established groundbreaking treatment targets that combine physician-reported outcomes with patient-reported outcomes for optimal atopic dermatitis management. These consensus guidelines, developed by 80 international experts across 40 countries, define minimal disease activity as achieving both EASI-90 (90% improvement in EASI) and itch scores of 0 to 1 simultaneously within 3 to 6 months of treatment initiation.
The treat-to-target approach addresses therapeutic inertia, a significant challenge in dermatology where clinicians may hesitate to switch treatments despite suboptimal outcomes. The AHEAD recommendations provide clear benchmarks for treatment success, emphasizing that visual skin improvement alone is insufficient if patients continue experiencing significant itch and quality-of-life impairment. This paradigm shift moves away from paternalistic medicine and toward patient-centered care that prioritizes symptoms most important to patients’ daily functioning.
Implementation of the AHEAD recommendations requires dermatologists to regularly assess both objective measures (skin clearance) and subjective experiences (itch, sleep disruption, psychological impact). The guidelines establish specific timelines for treatment evaluation and switching, providing clinicians with evidence-based criteria for therapeutic decisions. This systematic approach ensures patients achieve meaningful disease control rather than accepting partial responses that leave significant symptom burden unaddressed.
